ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

florensocatib

Also written as “HSK31858, tablet”, “HSK31858” and “HSK31858 tablets”.

Its studies are mostly in Bronchiectasis · Asthma, led by 2 companies.

Drug pageFlorensocatib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 202416 company-led studies, 13 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Groupits history only1310 open or runningphase 3since Sep 23, 2024Aug 16, 2021Nov 2026phase 1 · NCT07915024
Chiesi Farmaceutici33 open or runningphase 3since Apr 27, 2026Apr 27, 2026Dec 9, 2026phase 1 · NCT07683793

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chiesi Farmaceutici only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2025Named florensocatibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, HSK31858, CHF10196
  2. Apr 27, 2026First study: phase 3 study in BronchiectasisFirst studyNCT07577804 · 904 planned
  3. Jun 26, 2026Phase 1 study in Healthy VolunteersNCT07683793 · 18 planned · United Kingdom
  4. Jul 23, 2026Phase 1 study in Healthy Male VolunteersNCT07744386 · 24 planned · United Kingdom

Ahead

  1. Dec 9, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07683793
  2. Dec 15, 2028Primary completion: phase 1 study in Healthy Male VolunteersNCT07744386
  3. Apr 2030Primary completion: phase 3 study in BronchiectasisNCT07577804

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Chiesi Farmaceutici leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07744386Healthy Male Volunteers · United Kingdom1Not yet recruitingDec 15, 202824
NCT07683793Healthy Volunteers · United Kingdom1Not yet recruitingDec 9, 202618
NCT07577804Bronchiectasis3Not yet recruitingApr 2030904

How it is read

Names in the registry

  • “HSK31858, tablet”, 4 entries
  • “HSK31858”, 3 entries
  • “HSK31858 tablets”, 2 entries
  • “CHF10196”, 2 entries
  • “HSK31858 tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.